FR15C0084I2 - Vaccin contre les virus hpv16 et hpv18 et au moins un autre type de hpv selectionne parmi hpv 31, 45 ou 52 - Google Patents

Vaccin contre les virus hpv16 et hpv18 et au moins un autre type de hpv selectionne parmi hpv 31, 45 ou 52

Info

Publication number
FR15C0084I2
FR15C0084I2 FR15C0084C FR15C0084C FR15C0084I2 FR 15C0084 I2 FR15C0084 I2 FR 15C0084I2 FR 15C0084 C FR15C0084 C FR 15C0084C FR 15C0084 C FR15C0084 C FR 15C0084C FR 15C0084 I2 FR15C0084 I2 FR 15C0084I2
Authority
FR
France
Prior art keywords
hpv
type
vaccine against
against hpv16
hpv18
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR15C0084C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0413510.9A external-priority patent/GB0413510D0/en
Priority claimed from US11/114,301 external-priority patent/US20050287161A1/en
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Publication of FR15C0084I1 publication Critical patent/FR15C0084I1/fr
Application granted granted Critical
Publication of FR15C0084I2 publication Critical patent/FR15C0084I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FR15C0084C 2004-06-16 2015-12-04 Vaccin contre les virus hpv16 et hpv18 et au moins un autre type de hpv selectionne parmi hpv 31, 45 ou 52 Active FR15C0084I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0413510.9A GB0413510D0 (en) 2004-06-16 2004-06-16 Vaccine
US11/114,301 US20050287161A1 (en) 2002-12-20 2005-04-26 Vaccine
PCT/EP2005/006461 WO2005123125A1 (fr) 2004-06-16 2005-06-14 Vaccin contre les virus hpv16 et hpv18 et au moins un autre type de hpv selectionne parmi hpv 31, 45 ou 52

Publications (2)

Publication Number Publication Date
FR15C0084I1 FR15C0084I1 (fr) 2016-01-08
FR15C0084I2 true FR15C0084I2 (fr) 2016-10-28

Family

ID=35160037

Family Applications (2)

Application Number Title Priority Date Filing Date
FR15C0084C Active FR15C0084I2 (fr) 2004-06-16 2015-12-04 Vaccin contre les virus hpv16 et hpv18 et au moins un autre type de hpv selectionne parmi hpv 31, 45 ou 52
FR15C0082C Active FR15C0082I2 (fr) 2004-06-16 2015-12-04 Vaccin contre les virus hpv16 et hpv18 et au moins un autre type de hpv selectionne parmi hpv 31, 45 ou 52

Family Applications After (1)

Application Number Title Priority Date Filing Date
FR15C0082C Active FR15C0082I2 (fr) 2004-06-16 2015-12-04 Vaccin contre les virus hpv16 et hpv18 et au moins un autre type de hpv selectionne parmi hpv 31, 45 ou 52

Country Status (18)

Country Link
EP (1) EP1758609B1 (fr)
JP (1) JP2008502633A (fr)
KR (1) KR20070029254A (fr)
AR (1) AR049354A1 (fr)
AU (1) AU2005253723B2 (fr)
BR (1) BRPI0512042B8 (fr)
CA (1) CA2566620C (fr)
FR (2) FR15C0084I2 (fr)
IL (1) IL179138A0 (fr)
LU (3) LU92899I2 (fr)
MA (1) MA28692B1 (fr)
MX (1) MXPA06014515A (fr)
NO (1) NO20070195L (fr)
PE (1) PE20060434A1 (fr)
PL (1) PL1758609T3 (fr)
RU (1) RU2420313C2 (fr)
SG (1) SG153837A1 (fr)
WO (1) WO2005123125A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR053715A1 (es) * 2005-04-26 2007-05-16 Glaxosmithkline Biolog Sa Vacuna multivalente de vph
CN102159239A (zh) * 2008-07-31 2011-08-17 葛兰素史密斯克莱生物公司 针对hpv的疫苗
CN104288763B (zh) * 2009-06-19 2018-03-06 艾金株式会社 宫颈癌疫苗
AU2011279365A1 (en) * 2010-07-15 2013-03-07 British Columbia Cancer Agency Branch Human papillomavirus E7 antigen compositions and uses thereof
CA2885145A1 (fr) 2012-10-30 2014-05-08 Redvax Gmbh Vaccins recombinants a base de particules contre l'infection par le cytomegalovirus humain
CN107001430A (zh) * 2014-10-24 2017-08-01 哈普威克斯有限责任公司 癌症和皮肤病变治疗
CN107188966B (zh) 2016-03-15 2020-03-31 中国医学科学院基础医学研究所 一种乳头瘤病毒嵌合蛋白及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
GB9921147D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
US6908613B2 (en) * 2000-06-21 2005-06-21 Medimmune, Inc. Chimeric human papillomavirus (HPV) L1 molecules and uses therefor
GB0110431D0 (en) * 2001-04-27 2001-06-20 Glaxosmithkline Biolog Sa Novel compounds
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206359D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
PT1572233E (pt) * 2002-12-20 2011-06-07 Glaxosmithkline Biolog Sa Utilização de hpv16 e hpv18 como vacina contra um ou mais de tipos de hpv oncogénicos 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68

Also Published As

Publication number Publication date
LU92899I2 (fr) 2016-03-08
JP2008502633A (ja) 2008-01-31
LU92900I2 (fr) 2016-03-08
AU2005253723B2 (en) 2011-01-20
FR15C0084I1 (fr) 2016-01-08
NO20070195L (no) 2007-01-15
SG153837A1 (en) 2009-07-29
CA2566620A1 (fr) 2005-12-29
EP1758609B1 (fr) 2012-10-03
KR20070029254A (ko) 2007-03-13
MA28692B1 (fr) 2007-06-01
EP1758609A1 (fr) 2007-03-07
PL1758609T3 (pl) 2013-02-28
AR049354A1 (es) 2006-07-19
MXPA06014515A (es) 2007-03-23
LU92898I2 (fr) 2016-03-08
CA2566620C (fr) 2014-03-11
PE20060434A1 (es) 2006-06-08
FR15C0082I2 (fr) 2016-10-28
FR15C0082I1 (fr) 2016-01-08
WO2005123125A1 (fr) 2005-12-29
AU2005253723A1 (en) 2005-12-29
RU2420313C2 (ru) 2011-06-10
BRPI0512042B1 (pt) 2019-01-22
BRPI0512042A (pt) 2008-02-06
BRPI0512042B8 (pt) 2021-05-25
IL179138A0 (en) 2007-03-08
RU2006143804A (ru) 2008-08-20

Similar Documents

Publication Publication Date Title
FR15C0084I2 (fr) Vaccin contre les virus hpv16 et hpv18 et au moins un autre type de hpv selectionne parmi hpv 31, 45 ou 52
NO2017005I1 (no) Human pappilomavirus vaksine [type 6, 11, 16, 18, 31, 33, 45, 52, 58]
DK1375670T3 (da) Rekombinante mæslingevira, der udtrykker epitoper af RNA-viras antigener, samt anvendelse af de rekombinante vira til fremstilling af vaccinesammensætninger
AP2313A (en) Inhibitors of hepatitis C virus RNA-dependent RNA ploymerase, and compositions and treatments using the same.
PL2281831T3 (pl) Szczepionka przeciw wirusowi ospy wietrznej i półpaśca
IL189329A (en) The vaccine against dengue fever virus infection has been used and used
BRPI0309631A2 (pt) vacina tetravalente da dengue contendo uma trivial deleção de 30 nucleotídeos na utr-31' dos tipos de dengue 1,2,3,e 4, ou de vírus antigênicos quiméricos da dengue 1,2,3 e 4
WO2010047830A3 (fr) Agent permettant le traitement du virus de l'hépatite c
WO2009039248A8 (fr) Méthodes de traitement d'une infection par un virus de la famille des flaviviridae et compositions pour le traitement d'une infection par un virus de la famille des flaviviridae
MY139031A (en) Vaccine composition comprising virus-like particles of human papillomavirus
BRPI0811499A2 (pt) Métodos para purificar um vírus ou antígeno viral, e para preparar uma vacina contra um vírus ou antígeno viral.
HUS1500059I1 (hu) A HPV16 és HPV18 és a HPV 31, 45 vagy 52 közül legalább egy másik HPV típus elleni vakcina
MY144492A (en) Human papillomavirus vaccine comprising hpv 16 and hpv 18 virus like particles, which induce cross protection against other hpv types
EP1723238A4 (fr) Virus oncolytiques modifies
WO2007130616A3 (fr) Polyamides destinés au traitement du papillomavirus humain
EP1570067A4 (fr) Methodes et compositions d'immunisation contre le virus vih
WO2005023849A3 (fr) Peptides antigeniques du virus rabique et leurs utilisations
EP1765330A4 (fr) Derives de pyranoindole et utilisation de ceux-ci pour le traitement d'une maladie ou d'une infection provoquee par le virus de l'hepatite c
NO20053348D0 (no) Farmasoytisk sammensetning for behandling av virusangrep.
FR15C0080I2 (fr) Vaccin contre les virus hpv16 et hpv18 et au moins un autre type de hpv selectionne parmi hpv 31, 45 ou 52
WO2006024240A3 (fr) Composition vaccinale contre le virus de l'hepatite c
EP1539938A4 (fr) Virus gb-b (gbv-b) chimerique
WO2006019841A3 (fr) S
AU2003240866A1 (en) Antibodies, peptides and vaccines against hiv-1 virus
HK1103634A (en) Vaccine against hpv16 and hpv18 and at least another hpv type selected from hpv 31, 45 or 52